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Echinocandins are currently considered the first-line
treatment for invasive candidiasis (IC) in the intensive
care unit (ICU) [1, 2]. However, extracorporeal mem-
brane oxygenation (ECMO), a rescue therapy used in
patients with severe acute respiratory distress syndrome
(ARDS) [3], could alter the pharmacokinetics of certain
drugs [4]. We prescribed anidulafungin for suspected IC
in a patient with severe ARDS on ECMO and measured
the plasma concentrations of the drug using high-
performance liquid chromatography (HPLC).
A 69-year-old male patient was admitted to the ICU
with septic shock secondary to peritonitis. The anti-
infective treatment was based on surgical source control
and broad spectrum antimicrobial therapy, including
anidulafungin at usual doses. The patient developed
severe ARDS. ECMO with Novalung iLA Activve™ was
initiated, maintaining ultraprotective ventilation. Fem-
oral (23 F) and jugular (19 F) cannulas (Novalung™,
Germany) were inserted with 4.5 L/min blood flow and
4 L/min gas flow. Urine samples and pre-filter and post-
filter blood samples were collected before starting the
eight-dose anidulafungin infusion and 0.5, 1, 1.5, 2, 4, 6,
8, and 24 h after the infusion ended. Anidulafungin was
well tolerated without relevant adverse effects.
A non-compartmental pharmacokinetic analysis was
performed using Abbottbase Pharmacokinetic Systems™
(Abbott Laboratories, Illinois, USA). The maximum and
trough plasma concentrations (Cmax and Cmin, respect-
ively) were estimated directly from concentration-time
data. The area under the plasma concentration-time
curve over the 24-h dosing interval (AUC0–24) was
estimated using the linear trapezoidal rule for both pre-
filter and post-filter data. Clearance (CL) was estimated
as dose/AUC0–24. The apparent volume of distribution at
steady state (Vss) was estimated as the product of CL
and mean residence time (MRT).
Cmax and Cmin were 13.5 and 2.19 mg/L, respectively
(Fig. 1). Pre-filter and post-filter AUC0–24 were 107 and
111 mg/h/L, respectively; Vss was 18.9 L; CL was
0.933 L/h. Urine anidulafungin concentrations were neg-
ligible. All pharmacokinetic data were comparable to
published data in critically ill patients with and without
other types of extracorporeal support [5].
Regarding the use of anti-infective drugs in patients
on ECMO, most pharmacokinetic data on this topic are
from neonatal studies of antibiotics [4]. To the best of
our knowledge, this report is the first on the pharmaco-
kinetics of anidulafungin in a critically ill patient on
ECMO. In our case, the therapy had little effect on the
pharmacokinetics, suggesting that the dose of anidula-
fungin does not need adjustment. However, future stud-
ies are needed to confirm these findings.
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Fig. 1 Plasma anidulafungin concentrations over 24 h. Solid and dotted lines represent the concentrations in the pre-filter and post-filter sides of
the membrane, respectively. Urine concentrations of anidulafungin were very low and close to the limit of detection for the analytical procedure
used (0.05 mg/L)
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